Related articles in EMJ
Active Surveillance of Papillary Thyroid Cancer: Past, Present, and Future
Department of Surgery, Ewha Womans University College of Medicine, Seoul, KoreaCorrespondence to:
Received: February 16, 2021; Revised: March 11, 2021; Accepted: March 25, 2021
Ewha Med J 2021; 44(2): 37-40
Published April 30, 2021
Copyright © Ewha Womans University School of Medicine.
Active surveillance (AS) of papillary thyroid microcarcinoma was first suggested by Dr. Akira Miyauchi at Kuma Hospital in 1993. Based on several subsequent evidences, AS was approved by the American Thyroid Association in 2015. AS is no longer an experimental treatment but has become an acceptable standard of care for patients with low-risk thyroid cancers. No molecular markers, such as BRAF mutations, have been identified to predict the prognosis of papillary thyroid cancer. However, future molecular studies may reveal the relationship between genetic mutations and thyroid cancer prognosis. AS involves closely monitoring thyroid cancer over time, instead of immediately treating it with surgery. Patients and medical doctors should consider these two options: observation or surgery.
Thyroid neoplasms, History, Therapeutics, Surgery, Watchful waiting